<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="publisher-id">CI</journal-id><journal-id journal-id-type="publisher-id">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>e-Med</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17921092</article-id><article-id pub-id-type="pmc">2727972</article-id><article-id pub-id-type="publisher-id">ci079015</article-id><article-id pub-id-type="doi">10.1102/1470-7330.2007.9015</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><series-title>Article</series-title></article-categories><title-group><article-title>PET/CT and cross sectional imaging of gynecologic malignancy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Iyer</surname><given-names>Revathy B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Balachandran</surname><given-names>Aparna</given-names></name></contrib><contrib contrib-type="author"><name><surname>Devine</surname><given-names>Catherine E.</given-names></name></contrib></contrib-group><aff>Department of Diagnostic Radiology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA</aff><author-notes><corresp><italic>Corresponding address: Revathy B. Iyer, MD, 1515 Holcombe Boulevard, Unit 368, Houston, TX 77030, USA. Email</italic>: <email>riyer@mdanderson.org</email></corresp></author-notes><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>1</day><month>10</month><year>2007</year></pub-date><volume>7</volume><issue>Special issue A</issue><fpage>S130</fpage><lpage>S138</lpage><permissions><copyright-statement>&#x000a9; 2007 International Cancer Imaging Society</copyright-statement></permissions><abstract><title>Abstract</title><p>Gynecologic cancers are a common cause of morbidity and mortality in women of all ages. While many gynecologic cancers are staged clinically using the International Federation of Gynecology and Obstetrics (FIGO) staging system, imaging can be a useful adjunct to clinical staging. Cross sectional imaging techniques such as ultrasound (US), computed tomography (CT) and magnetic resonance imaging (MRI) have been used to detect and follow patients with gynecologic cancer. These imaging modalities can show anatomic detail and morphologic changes in the female genitourinary tract to good advantage. Positron emission tomography (PET) differs in that it shows functional information that is not easily obtained by the other cross sectional imaging techniques. The fusion of PET with CT allows anatomic localization of functional abnormalities in the female genital tract and thereby allows the detection of gross disease in many malignant conditions both within and outside the confines of the female pelvis. The utility and limitations of imaging common gynecologic tumors such as cervical, ovarian and endometrial cancer are discussed with particular emphasis on PET/CT imaging.</p></abstract><kwd-group><kwd>Cervical cancer</kwd><kwd>ovarian cancer</kwd><kwd>endometrial cancer</kwd><kwd>imaging</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Positron emission tomography (PET) has been used in oncologic imaging for about three decades now, however in the last several years scientific data has consolidated the utility of this biologic imaging technique in the diagnosis and management of patients with cancer. While many radiotracers have been studied, <sup>18</sup>F-fluoro-deoxyglucose (<sup>18</sup>F-FDG) PET is most widely in clinical use. <sup>18</sup>F-FDG has a physical half-life of 110&#x02009;min and is widely available, which makes it ideally suited for imaging. Elevated glucose metabolism in most tumor cells causes increased accumulation of this radiopharmaceutical. FDG competes with glucose for transport into the cell and is subsequently phosphorylated and trapped in the cell. The power of PET imaging comes from the ability to detect biological or functional characteristics of tumor cells rather than morphology alone.</p><p>While <sup>18</sup>F-FDG is a good radiotracer, it is not entirely specific for malignancy. High physiologic uptake may be seen in metabolically active normal tissues such as the brain, bowel, genitourinary tract, salivary glands, and lymphoid tissue. Inflammation or infection can also be metabolically active. Evaluation of the abdomen and pelvis can be particularly challenging because of FDG activity in the urinary collecting systems, ureters, and bladder as well occasional intense uptake in the cecum and rectosigmoid colon. The liver typically has a mottled appearance with moderate uptake while the spleen is typically less metabolically active and more homogeneous in appearance. In pre-menopausal women, physiological uptake is normal in the ovaries and uterus during various phases of the menstrual cycle and should not be confused with tumor.</p><p>The development of combined PET/computed tomography (CT) scanners allows the use of CT as the attenuation map to correct the FDG emission data. CT allows accurate anatomic definition of areas of increased FDG update and allows better differentiation of benign from malignant lesions yielding a more specific report. Lesion characterization on CT is also improved in the setting of low FDG uptake in some tumors such as mucinous adenocarcinomas. Mucinous lesions and associated calcification are well detected on CT but not demonstrated easily on FDG PET. Small, sub-centimeter lesions are also better characterized on CT since the metabolic rate in small lesions is often underestimated because of limits of resolution of PET scanners. FDG PET clearly has a role in the evaluation and management of patients with cancer. The following sections describe the role of FDG PET in the evaluation of patients with gynecologic malignancy.</p></sec><sec><title>Cervical cancer</title><p>Cervical cancer is the third most common gynecologic malignancy in the US with more than 10,000 new cases diagnosed each year resulting in an estimated 3700 deaths in 2007<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>. The histologic subtype that occurs most commonly is squamous cell carcinoma in about 90% of cases. Squamous cell carcinomas arise from the squamo-columnar junction near the external os in younger patients, resulting in exophytic lesions. As the squamo-columnar junction migrates toward the uterine body in older women, these tumors grow from the endocervix and may become quite large before they are diagnosed. Adenocarcinoma and adenosquamous carcinoma account for about 10% of cervical cancer cases with unusual histologies such as sarcoma and lymphoma being quite rare.</p><sec><title>Staging and treatment</title><p>Cervical cancer invades the cervical stroma and then spreads by direct invasion of parametrial tissues, uterus and vagina. Adjacent organs in the pelvis such as the bladder and rectum may be involved in more advanced disease. Hematogenous spread to the lungs, liver or bone is unusual at initial presentation although it may occur with advanced disease or recurrence. Lymphovascular invasion results in metastatic lymphadenopathy which is quite common. Metastatic nodes are typically seen along the internal iliac and external iliac chains in the pelvis with subsequent spread to the retroperitoneum. Inguinal adenopathy may be seen with lower vaginal involvement. Retrocrural, mediastinal and supraclavicular spread of adenopathy is seen with bulky disease in the abdomen.</p><p>When tumor is confined to the cervix and the overall tumor volume is small, surgical management can be curative and radical hysterectomy is typically performed. As tumor size increases and spread beyond the cervix into the parametrial tissues occurs, definitive radiotherapy and chemotherapy are generally used. Once a diagnosis of invasive cervical cancer is made, accurate staging is of great importance for treatment planning. Clinical staging relies primarily on physical examination, which may be difficult and erroneous particularly in those patients with advanced disease. The role of imaging is therefore to document the presence of extra-cervical spread to better define management of these patients (<xref ref-type="table" rid="T1">Table 1</xref>).
<table-wrap id="T1" position="float"><label><italic>Table 1</italic></label><caption><p><bold><italic>Cervix cancer FIGO staging</italic></bold></p></caption><table frame="hsides" rules="groups"><tbody align="left"><tr><th rowspan="1" colspan="1">Stage 0</th><th rowspan="1" colspan="1">Carcinoma in situ, CIN</th></tr><tr><td rowspan="1" colspan="1"><bold>Stage I</bold></td><td rowspan="1" colspan="1">Invasive carcinoma confined to the cervix</td></tr><tr><td rowspan="1" colspan="1"><bold>Stage I</bold></td><td rowspan="1" colspan="1">Diagnosed only by microscopy</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IA1</td><td rowspan="1" colspan="1">Micro-invasive carcinoma with stromal invasion &#x0003c;3&#x02009;mm depth, &#x0003c;7&#x02009;mm width</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IA2</td><td rowspan="1" colspan="1">Micro-invasive carcinoma &#x0003c;5&#x02009;mm depth, &#x0003c;7&#x02009;mm width</td></tr><tr><td rowspan="1" colspan="1"><bold>Stage IB</bold></td><td rowspan="1" colspan="1">Clinically visible or microscopic lesion &#x0003e;IA2</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IB1</td><td rowspan="1" colspan="1">Clinical lesion &#x0003c;4&#x02009;cm</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IB2</td><td rowspan="1" colspan="1">Clinical lesion &#x0003e;4&#x02009;cm</td></tr><tr><td rowspan="1" colspan="1"><bold>Stage II</bold></td><td rowspan="1" colspan="1">Extension beyond cervix but not to sidewall</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIA</td><td rowspan="1" colspan="1">Involvement of upper two-thirds of vagina</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIB</td><td rowspan="1" colspan="1">Parametrial involvement</td></tr><tr><td rowspan="1" colspan="1"><bold>Stage III</bold></td><td rowspan="1" colspan="1">Extension to pelvic wall and/or lower third of vagina; hydronephrosis</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIIA</td><td rowspan="1" colspan="1">Involvement of lower third of vagina</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIIB</td><td rowspan="1" colspan="1">Pelvic sidewall involvement; hydronephrosis</td></tr><tr><td rowspan="1" colspan="1"><bold>Stage IV</bold></td><td rowspan="1" colspan="1">Extension beyond true pelvis or involving bladder or rectum</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IVA</td><td rowspan="1" colspan="1">Involvement of bladder or rectal mucosa</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IVB</td><td rowspan="1" colspan="1">Spread outside true pelvis or metastasis to distant organs</td></tr></tbody></table></table-wrap></p></sec><sec><title>Imaging</title><p>Magnetic resonance imaging (MRI), with its superior soft tissue contrast resolution and multi-planar capabilities is well suited to image cervical cancer. T2 weighted MR images provide excellent detail of normal uterine and cervical anatomy and also demonstrate the primary tumor and its extent. Since the absence of parametrial invasion by tumor is important in determining if the patient may be a surgical candidate, MRI can be used to predict parametrial invasion with a negative predictive value of 95%<sup>[<xref ref-type="bibr" rid="B2">2</xref>]</sup>. Endocervical tumors may be difficult to evaluate clinically, but are well demonstrated by MR imaging. Stromal invasion by the primary tumor is also well delineated by MRI. The overall accuracy of MR staging of cervical cancer is reported to be about 90%<sup>[<xref ref-type="bibr" rid="B2">2,</xref><xref ref-type="bibr" rid="B3">3</xref>]</sup>.</p><p>CT is also used for evaluation of advanced disease, nodal involvement and distant metastasis although CT has had a limited role in evaluating the primary cervical tumor as tumors may be isodense to the normal cervix. FDG PET cannot be reliably used to determine the extent of local tumor invasion but definitely plays a role in the evaluation of metastatic disease, particularly lymph node metastases (<xref ref-type="fig" rid="F1">Fig. 1</xref>).
<fig id="F1" position="float"><label><italic>Figure 1</italic></label><caption><p><bold>A 37-year-old female with newly diagnosed squamous cell carcinoma of the cervix. (a) Sagittal T2-weighted MRI of the pelvis shows cervical tumor (arrowhead); (b) coronal fused PET/CT shows FDG avid primary tumor and adenopathy in the pelvis as well as uptake adjacent to the right hip (arrowheads), subsequently proven soft tissue metastasis; (c) axial fused PET/CT shows FDG avid adenopathy in the left supraclavicular fossa (arrowhead); (d) axial fused PET/CT also shows another FDG avid soft tissue metastasis in the right periscapular region (arrowhead).</bold></p></caption><graphic xlink:href="ci07901501"/></fig></p><p>Although the presence or absence of pelvic lymph node metastasis does not affect the FIGO clinical stage, lymphadenopathy is an important prognostic factor in patients with cervical carcinoma. While CT and MRI have been used to detect local extent of tumor, both of these cross sectional imaging modalities primarily rely on morphologic changes such as nodal size and therefore have difficulty detecting metastatic disease in &#x02018;normal sized&#x02019; lymph nodes (short axis diameter &#x0003c;1&#x02009;cm)<sup>[<xref ref-type="bibr" rid="B4">4,</xref><xref ref-type="bibr" rid="B5">5</xref>]</sup>. Other criteria such as inherent tissue contrast and contrast enhancement are also unreliable<sup>[<xref ref-type="bibr" rid="B6">6</xref>]</sup>. Lymphangiography, CT, and MRI have been shown to perform similarly in the detection of lymph node metastasis from cervical cancer with an overall accuracy estimated to be about 85%<sup>[<xref ref-type="bibr" rid="B7">7</xref>]</sup>.</p><p>Since FDG PET can demonstrate metabolically active sites of tumor spread, it has been shown to have a role in the staging and evaluation of lymph node involvement in patients with cervical cancer. PET has shown some promise in detecting lymph node metastases in the pelvis and retroperitoneum<sup>[<xref ref-type="bibr" rid="B8">8,</xref><xref ref-type="bibr" rid="B9">9</xref>]</sup>. Sironi <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B10">10</xref>]</sup> found that PET/CT proved to be valuable for lymph node staging in patients with early-stage cervical cancer with short-axis diameter greater than 0.5&#x02009;cm being the size threshold for accurate depiction of metastatic nodes. Bladder and ureteral activity can mask disease in the pelvis and can be overcome by having patient void or using continuous bladder irrigation. Focal areas of ureteral activity should not be confused with nodal disease</p><p>FDG PET may also be useful for determining treatment response and prognostication of patients. FDG PET has been used to predict survival in patients with cervical cancer. Grigsby <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B11">11</xref>]</sup> found that 2-year progression free survival was 64% in CT-negative, PET-negative patients; 18% in CT-negative, PET-positive patients; and dropped to 14% in CT-positive, PET-positive patients.</p><p>Approximately 1/3 of patients with invasive cervical cancer have recurrence after treatment. Conventional imaging cannot differentiate recurrence from treatment related fibrosis. PET activity may help distinguish tumor recurrence from post-therapy changes after the acute post-therapy changes have subsided in the pelvis.</p><p>In summary, the role of FDG PET is promising for primary staging of cervical carcinoma particularly since it appears to be more accurate than cross-sectional imaging (CT/MRI) for determining lymph node involvement. It is also helpful for determining prognosis of disease and finding recurrent disease. It is important to keep in mind the limitations of PET. It may not resolve &#x02018;small&#x02019; lesions such as lung lesions that are &#x0003c;6&#x02009;mm, liver lesions that are &#x0003c;1&#x02009;cm and brain metastases due to the inherent high glucose uptake in the normal brain. Diffuse peritoneal carcinomatosis can be difficult to detect because of bowel activity. FDG avid lesions may also be benign such as acute infections, as well as granulomatous processes such as tuberculosis and sarcoid. It is also important to keep in mind false negative lesions that may not take up FDG such as mucinous tumors.</p></sec></sec><sec><title>Ovarian cancer</title><p>Ovarian cancer is the second most common gynecological malignancy accounting for about 22,220 new cases per year<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>. It is, however, the most common cause of cancer related death from gynecological malignancy and the fifth leading cause of cancer related death in women<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>. While most cases are sporadic, risk factors include nulliparity, early menarche, and late menopause. Many patients with ovarian cancer present with non-specific symptoms such as abdominal bloating and increased distension. These non-specific symptoms lead to a delay in diagnosis and later stage of disease at presentation<sup>[<xref ref-type="bibr" rid="B12">12</xref>]</sup>.</p><p>The majority of ovarian cancers, up to 85%, arise from the surface epithelium of the ovary<sup>[<xref ref-type="bibr" rid="B13">13</xref>]</sup>. Of the epithelial tumors, the most common type is serous adenocarcinoma. The remaining 15% of all ovarian cancers are germ cell tumors (such as teratomas, dysgerminomas and yolk sac tumors), sex cord stromal tumors (such as fibromas and thecomas) and least commonly, metastatic ovarian cancer from other primary tumors, particularly those of gastric, colonic and pancreatic origin (<xref ref-type="table" rid="T2">Table 2</xref>).
<table-wrap id="T2" position="float"><label><italic>Table 2</italic></label><caption><p><bold><italic>Ovarian cancer staging</italic></bold></p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">FIGO Stage</th><th rowspan="1" colspan="1">TNM stage</th><th rowspan="1" colspan="1">Disease extent</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1"><bold>I</bold></td><td rowspan="1" colspan="1">T1</td><td rowspan="1" colspan="1">Tumor limited to ovaries</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IA</td><td rowspan="1" colspan="1">T1a</td><td rowspan="1" colspan="1">Tumor limited to one ovary, no malignant ascites, no tumor on the external surface, capsule intact</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IB</td><td rowspan="1" colspan="1">T1b</td><td rowspan="1" colspan="1">Tumor limited to both ovaries, no malignant ascites, no tumor on the external surface, capsule intact</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IC</td><td rowspan="1" colspan="1">T1c</td><td rowspan="1" colspan="1">Stage IA or IB with malignant ascites or capsule rupture or with tumor on the surface of one or both ovaries or with positive peritoneal washings</td></tr><tr><td rowspan="1" colspan="1"><bold>II</bold></td><td rowspan="1" colspan="1">T2</td><td rowspan="1" colspan="1">Tumor involves one or both ovaries with pelvic extension</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIA</td><td rowspan="1" colspan="1">T2a</td><td rowspan="1" colspan="1">Extension to involve the uterus or fallopian tubes, no malignant ascites</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIB</td><td rowspan="1" colspan="1">T2b</td><td rowspan="1" colspan="1">Extension to other pelvic tissues, no malignant ascites</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIC</td><td rowspan="1" colspan="1">T2c</td><td rowspan="1" colspan="1">Stage IIB or IIC with malignant ascites, or capsule rupture or with tumor on the surface of one or both ovaries or with positive peritoneal washings</td></tr><tr><td rowspan="1" colspan="1"><bold>III</bold></td><td rowspan="1" colspan="1">T3</td><td rowspan="1" colspan="1">Tumor involves one or both ovaries with microscopic peritoneal metastases outside the pelvis</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIIA</td><td rowspan="1" colspan="1">T3a</td><td rowspan="1" colspan="1">Microscopic peritoneal metastasis beyond the pelvis and nodes are negative</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIIB</td><td rowspan="1" colspan="1">T3b</td><td rowspan="1" colspan="1">Macroscopic peritoneal metastasis beyond the pelvis, 2&#x02009;cm or less in size and nodes are negative</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;IIIC</td><td rowspan="1" colspan="1">T3c</td><td rowspan="1" colspan="1">Peritoneal metastasis greater than 2&#x02009;cm in size and/or retroperitoneal or &#x000b1;N1 inguinal lymph node metastasis</td></tr><tr><td rowspan="1" colspan="1"><bold>IV</bold></td><td rowspan="1" colspan="1">M1</td><td rowspan="1" colspan="1">Distant metastasis including involvement of liver parenchyma</td></tr></tbody></table></table-wrap></p><sec><title>Imaging ovarian masses</title><p>Ultrasound is the study of choice in the initial evaluation of known or suspected adnexal masses<sup>[<xref ref-type="bibr" rid="B14">14</xref>]</sup>. It is sensitive in detection, inexpensive and widely available. Suspicious features seen on ultrasound include the presence of thick nodular walls or septations (&#x0003e;3&#x02009;mm), papillary projections and echogenic loculations or solid areas<sup>[<xref ref-type="bibr" rid="B15 B16 B17 B18">15&#x02013;18</xref>]</sup>. The sensitivity of gray scale ultrasound criteria in predicting malignancy in ovarian tumors has been shown to be between 85 and 97%, whereas its specificity ranges from 56 to 95%. In addition to the gray scale evaluation, color and pulsed Doppler ultrasound have also been used in the evaluation of ovarian masses, although overlap of Doppler indices between malignant and benign lesions limits the usefulness of this technique<sup>[<xref ref-type="bibr" rid="B19 B20 B21 B22 B23">19&#x02013;23</xref>]</sup>.</p><p>MRI can be used to further evaluate sonographically indeterminate ovarian masses due to the better tissue contrast resolution seen with MR imaging. MRI is useful in the diagnosis of benign lesions, such as mature cystic teratomas (containing fat), endometriomas (containing blood products), and non-degenerative leiomyomas in the adnexa<sup>[<xref ref-type="bibr" rid="B24">24,</xref><xref ref-type="bibr" rid="B25">25</xref>]</sup>. The findings most predictive of malignancy on MRI are papillary projections, necrosis in a solid tumor, and septations, which can be readily detected on contrast-enhanced MRI.</p><p>CT can be used in the staging of ovarian cancer, but is of limited utility in the characterization of a known ovarian mass. CT is of help in characterizing mature cystic teratomas containing fat.</p><p>PET using FDG has been evaluated for the diagnosis and characterization of ovarian masses. Hypermetabolic ovarian lesions, which were more intense than physiologic liver uptake have been considered positive for malignancy in most studies. Some of the studies used a cut off value of standardized uptake value (SUV) greater than or equal to 3 to be highly suggestive of malignancy. However, in menstruating women, false positive FDG uptake has been seen in follicular cysts and in corpus luteum cysts, between day 10 and day 25 of the menstrual cycle. Scanning pre-menopausal women before day 10 of the cycle can help distinguish physiologic uptake in the ovaries. False positive findings have also been seen in benign cystadenomas, teratomas, schwannomas, endometriomas and other inflammatory processes of the ovary. FDG uptake in the ovaries in post-menopausal women is usually concerning and must be further evaluated, typically with ultrasound.</p><p>In early studies, PET imaging demonstrated high sensitivity and specificity for the diagnosis of ovarian malignancy. This may have been due to lack of pathological proof in the earlier studies. In subsequent studies, the sensitivities and specificities of FDG PET in the diagnosis of ovarian cancer has been between 58 and 86% and 54 and 86% respectively in women with adnexal masses<sup>[<xref ref-type="bibr" rid="B26">26,</xref><xref ref-type="bibr" rid="B27">27</xref>]</sup>. In a study by Kawahara <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B28">28</xref>]</sup>, a total of 38 patients were evaluated. PET imaging showed a sensitivity of 78% and a specificity of 87% compared with 91% and 87% respectively for MRI. False positive results were seen for cystadenomas and dermoid tumors and false negative results were seen in borderline ovarian tumors and mucinous adenocarcinoma of the ovary. In a study by Grab <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B29">29</xref>]</sup>, 101 asymptomatic adnexal masses were evaluated by ultrasound, MRI and PET. The sensitivity and specificity of PET was 58% and 80% compared with 90% and 60% with ultrasound and 83% and 84% with MRI. False positive results in benign cystadenomas and endometriosis were noted in this study with false negative results in the case of borderline tumors of the ovary. In a study of Fenchel <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B30">30</xref>]</sup>, false negative PET findings were obtained in cystadenocarcinoma and ovarian tumors with low malignant potential, and false positive PET results were obtained in acute inflammatory processes, benign schwannoma, teratoma, cystadenoma, and endometriomas. FDG accumulation in the ovary can also occur related to follicular and corpus luteum cysts resulting in false positive imaging results. This was shown to occur in 20% of pre-menopausal women in a study by Kim <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B31">31</xref>]</sup>.</p><p>Due to the false positive results in benign ovarian conditions and the false negative results in borderline tumors and early stage ovarian cancer, the role of FDG PET imaging for the initial diagnosis of ovarian cancer is limited.</p></sec><sec><title>Clinical staging and treatment</title><p>Once a diagnosis of ovarian cancer has been established, accurate staging is critical in planning treatment. The prognosis and 5-year survival in patients with ovarian cancer is dependent on the stage at diagnosis and ranges from 80% for stage I disease to 8% for stage IV disease. Ovarian cancer can spread locally within the pelvis, with subsequent spread within the peritoneal cavity to the rest of the abdomen. Tumor spread can also occur via lymphatics and hematogenously. Lymphadenopathy can be seen in the inguinal, pelvic and para-aortic regions. Hematogenous sites of spread include the liver and lung.</p><p>The standard of care for suspected early ovarian cancer is a comprehensive staging laparotomy which also provides tissue to establish a histologic diagnosis. A comprehensive staging laparotomy consists of a total abdominal hysterectomy, bilateral salpingooophorectomy, infracolic omentectomy, random sampling of multiple peritoneal sites (including pelvic side walls, paracolic gutters, cul-de-sac, and surface of bladder, rectum, and diaphragm), and pelvic and para-aortic lymphadenectomy. Optimal debulking refers to the surgical resection of all tumor sites to a maximal diameter of less than 1&#x02009;cm<sup>[<xref ref-type="bibr" rid="B32">32</xref>]</sup>. Clinical trials have shown that optimal surgical debulking is associated with a more favorable response to post-operative chemotherapy and, therefore, prolonged survival. The role of pre-operative imaging in identifying patients who are potential candidates for optimal debulking surgery is extremely important.</p></sec><sec><title>Imaging and staging</title><p>There are few studies evaluating the additional role of PET imaging to CT imaging in the pre-operative staging of ovarian cancer. Yoshida <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B33">33</xref>]</sup> evaluated 15 patients who underwent PET in addition to CT to detect tumor spread. The sensitivity and specificity of CT alone was 72% and 81% compared with 76% and 82% with the addition of PET. The accuracy of staging improved from 53% with CT alone to 87% with CT and PET. This study concluded that the addition of PET to CT improved the diagnostic accuracy in the staging of ovarian cancer. This study also showed increased FDG uptake in malignant but normal sized para-aortic nodes. Yuan <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B34">34</xref>]</sup> in a study of five patients with recurrent ovarian cancer also demonstrated that PET imaging can detect metastases even in normal sized lymph nodes. The detection of sub-centimeter peritoneal implants is limited both on CT and on PET imaging. PET imaging in addition is limited by the spatial resolution and the physiologic activity seen in the bowel, ureters and bladder. Physiologic FDG uptake in the ureters, bladder, and bowel can mimic peritoneal implants. Some authors have suggested the use of hydration, diuretics and voiding prior to image acquisition in order to minimize the effects from ureteric and bladder activity. The use of combined PET/CT can also help decrease false positives related to by better anatomic localization of normal structures.</p></sec><sec><title>Recurrent ovarian cancer</title><p>CT imaging is the most commonly used imaging modality in patients with suspected recurrent ovarian cancer. With the advent of thin section, multidetector CT, smaller metastatic deposits are diagnosed on CT. However, the accuracy of CT drops to 25&#x02013;50% for peritoneal implants less than 1&#x02009;cm in size<sup>[<xref ref-type="bibr" rid="B35">35</xref>]</sup>. Studies have reported that PET imaging may be of help in patients to detect recurrence due to the high tumor to background FDG uptake. The sensitivity of PET ranges from 80 to 100% and the specificity ranges from 42 to 100%. Some of these studies were performed on patients with elevated tumor marker levels and negative/equivocal CT imaging.</p><p>PET imaging is also limited in the ability to detect small metastatic deposits and can be limited due to physiologic bowel and bladder activity. In a study by Nakomoto <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B36">36</xref>]</sup>, the overall sensitivity improved from 72.7 to 92.3% and specificity improved from 75 to 100% with the addition of PET to CT imaging. Picchio <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B37">37</xref>]</sup> showed increase in sensitivity from 70 to 83% and increase in specificity from 83 to 92% with the addition of PET to CT compared with CT imaging alone. Bristow <italic>et al</italic>.<sup>[<xref ref-type="bibr" rid="B38">38</xref>]</sup> evaluated combined PET/CT in the detection of tumor recurrence. The sensitivity and accuracy was 83% and 82% respectively. There is a definite role for PET imaging in patients with elevated tumor marker levels (CA 125 levels) and negative/equivocal CT imaging. With the increasing use of combined PET/CT imaging, the additive roles of PET and CT imaging can be utilized in patients undergoing follow up with elevated tumor marker levels (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Future prospective studies evaluating these patients along with histopathologic correlation maybe beneficial.
<fig id="F2" position="float"><label><italic>Figure 2</italic></label><caption><p><bold>A 56-year-old female with recurrent ovarian cancer. (a) Coronal PET image shows multiple sites of FDG recurrent disease in the chest, abdomen and pelvis (arrowheads); (b) axial fused PET/CT localizes one site of FDG uptake to the sigmoid colon which proved to be metastatic ovarian cancer involving the colon.</bold></p></caption><graphic xlink:href="ci07901502"/></fig></p></sec></sec><sec><title>Endometrial carcinoma</title><p>Endometrial cancer is a common gynecologic malignancy which develops in approximately 142,000 women and is responsible for an estimated 42,000 deaths worldwide each year<sup>[<xref ref-type="bibr" rid="B39">39</xref>]</sup>. In the United States, endometrial cancer is the fourth most common malignancy in women overall and the most common gynecologic cancer and is the eighth most common cause of death in women<sup>[<xref ref-type="bibr" rid="B1">1</xref>]</sup>.</p><p>The majority of cases occur in post-menopausal women with the highest incidence in the seventh decade of life. Abnormal uterine bleeding is the most frequent clinical presentation of endometrial cancer, leading to early diagnosis in the majority of patients. The overall 5-year survival of patients with endometrial cancer is around 80%, but there is a substantial prognostic difference depending on stage, myometrial invasion, and histological type<sup>[<xref ref-type="bibr" rid="B39">39</xref>]</sup>. The overall prognosis is poor in advanced or recurrent endometrial carcinoma<sup>[<xref ref-type="bibr" rid="B40">40</xref>]</sup>.</p><sec><title>Diagnosis, staging, treatment</title><p>The diagnosis of endometrial cancer is usually established by histology from endometrial biopsy. Staging is based on extent of the primary tumor, regional lymph node involvement, and presence or absence of distant metastases. The FIGO staging of endometrial cancer is used and patients are typically staged surgically<sup>[<xref ref-type="bibr" rid="B39">39</xref>]</sup>. Lymphatic spread is via obturator nodes or internal iliac nodes, and subsequently to retroperitoneal nodes with rare direct para-aortic spread without pelvic disease<sup>[<xref ref-type="bibr" rid="B41">41</xref>]</sup>.</p><p>Treatment for endometrial cancer is total abdominal hysterectomy with or without lymph node dissection. Systemic treatment is used for palliative purposes in the setting of metastatic or advanced disease<sup>[<xref ref-type="bibr" rid="B39">39</xref>]</sup>. Neo-adjuvant therapy chemotherapy may be used in select cases for pre-operative down-staging (<xref ref-type="table" rid="T3">Table 3</xref>).
<table-wrap id="T3" position="float"><label><italic>Table 3</italic></label><caption><p><bold><italic>TNM staging system for endometrial carcinoma (American Joint Committee on Cancer, 2002)</italic></bold></p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">TNM category</th><th rowspan="1" colspan="1">FIGO stages</th><th rowspan="1" colspan="1">Description</th></tr></thead><tbody align="left"><tr><td colspan="3" rowspan="1"><italic><bold>Primary tumor (T)</bold></italic></td></tr><tr><td rowspan="1" colspan="1">TX</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Primary tumor cannot be assessed</td></tr><tr><td rowspan="1" colspan="1">T0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">No evidence of primary tumor</td></tr><tr><td rowspan="1" colspan="1">Tis</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">Carcinoma <italic>in situ</italic></td></tr><tr><td rowspan="1" colspan="1">T1</td><td rowspan="1" colspan="1">I</td><td rowspan="1" colspan="1">Tumor confined to corpus uteri</td></tr><tr><td rowspan="1" colspan="1">T1a</td><td rowspan="1" colspan="1">IA</td><td rowspan="1" colspan="1">Tumor limited to endometrium</td></tr><tr><td rowspan="1" colspan="1">T1b</td><td rowspan="1" colspan="1">IB</td><td rowspan="1" colspan="1">Tumor invades less than one-half of the myometrium</td></tr><tr><td rowspan="1" colspan="1">T1c</td><td rowspan="1" colspan="1">IC</td><td rowspan="1" colspan="1">Tumor invades one-half or more of the myometrium</td></tr><tr><td rowspan="1" colspan="1">T2</td><td rowspan="1" colspan="1">II</td><td rowspan="1" colspan="1">Tumor invades cervix but does not extend beyond uterus</td></tr><tr><td rowspan="1" colspan="1">T2a</td><td rowspan="1" colspan="1">IIA</td><td rowspan="1" colspan="1">Tumor limited to the glandular epithelium of the endocervix; there is no evidence of connective tissue stromal invasion</td></tr><tr><td rowspan="1" colspan="1">T2b</td><td rowspan="1" colspan="1">IIB</td><td rowspan="1" colspan="1">Invasion of the stromal connective tissue of the cervix</td></tr><tr><td rowspan="1" colspan="1">T3</td><td rowspan="1" colspan="1">III</td><td rowspan="1" colspan="1">Local and/or regional spread as defined below</td></tr><tr><td rowspan="1" colspan="1">T3a</td><td rowspan="1" colspan="1">IIIA</td><td rowspan="1" colspan="1">Tumor involves serosa and/or adnexa (direct extension or metastasis) and/or cancer cells in ascites or peritoneal washings</td></tr><tr><td rowspan="1" colspan="1">T3b</td><td rowspan="1" colspan="1">IIIB</td><td rowspan="1" colspan="1">Vaginal involvement (direct extension or metastasis)</td></tr><tr><td rowspan="1" colspan="1">T4</td><td rowspan="1" colspan="1">IVA</td><td rowspan="1" colspan="1">Tumor involves bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumor as T4)</td></tr><tr><td colspan="3" rowspan="1"><italic><bold>Regional lymph nodes (N)</bold></italic></td></tr><tr><td rowspan="1" colspan="1">NX</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Regional lymph nodes cannot be assessed</td></tr><tr><td rowspan="1" colspan="1">N0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">No regional lymph node metastasis</td></tr><tr><td rowspan="1" colspan="1">N1</td><td rowspan="1" colspan="1">IIIC</td><td rowspan="1" colspan="1">Regional lymph node metastasis to pelvic and/or para-aortic nodes</td></tr><tr><td colspan="3" rowspan="1"><italic><bold>Distant metastasis (M)</bold></italic></td></tr><tr><td rowspan="1" colspan="1">MX</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Distant metastasis cannot be assessed</td></tr><tr><td rowspan="1" colspan="1">M0</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">No distant metastasis</td></tr><tr><td rowspan="1" colspan="1">M1</td><td rowspan="1" colspan="1">IVB</td><td rowspan="1" colspan="1">Distant metastasis (includes metastasis to abdominal lymph nodes other than para-aortic, and/or inguinal lymph nodes; excludes metastasis to vagina, pelvic serosa, or adnexa)</td></tr></tbody></table></table-wrap></p></sec><sec><title>Imaging</title><p>Endometrial cancer is surgically staged, but accurate assessment by pre-treatment imaging can potentially optimize surgical and non-surgical treatment particularly with regard to the use of pre-operative, neo-adjuvant therapy in advanced disease<sup>[<xref ref-type="bibr" rid="B42">42</xref>]</sup>. MR imaging is used to evaluate the depth of myometrial invasion and cervical invasion, which affects overall prognosis. The likelihood of lymphovascular invasion is greater with greater myometrial penetration of tumor. CT or MR may also be used to assess nodal involvement<sup>[<xref ref-type="bibr" rid="B43">43,</xref><xref ref-type="bibr" rid="B44">44</xref>]</sup>. CT and MRI criteria for metastatic lymphadenopathy are based mostly on size criteria. PET imaging has been shown to be more accurate in identifying metastatic lymph nodes, particularly in nodes considered normal by size criteria (<xref ref-type="fig" rid="F3">Fig. 3</xref>)<sup>[<xref ref-type="bibr" rid="B45">45,</xref><xref ref-type="bibr" rid="B46">46</xref>]</sup>.
<fig id="F3" position="float"><label><italic>Figure 3</italic></label><caption><p><bold>A 74-year-old female with endometrial cancer. (a) CT shows small retroperitoneal nodes that measure less than 1&#x02009;cm; (b) axial PET/CT shows FDG uptake in these nodes, subsequently proven metastases.</bold></p></caption><graphic xlink:href="ci07901503"/></fig></p><p>Like most neoplasms, endometrial carcinoma does demonstrate an increased rate of glycolysis and takes up FDG<sup>[<xref ref-type="bibr" rid="B47">47</xref>]</sup>. There have been case reports of endometrial cancer diagnosed incidentally by PET<sup>[<xref ref-type="bibr" rid="B48">48,</xref><xref ref-type="bibr" rid="B49">49</xref>]</sup>. Malignant uptake in the endometrium has been shown to have a mean SUV of 18.8 &#x000b1; 9<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>.</p><p>Non-malignant, physiologic causes of increased <sup>18</sup>F-FDG uptake in the endometrium must be taken into account in the routine interpretation of PET/CT images. In pre-menopausal patients, normal endometrial uptake of <sup>18</sup>F-FDG varies cyclically, increasing during the menstrual and ovulatory phases of the cycle<sup>[<xref ref-type="bibr" rid="B40">40,</xref><xref ref-type="bibr" rid="B45">45</xref>]</sup>. Assessment of physiologic endometrial uptake has demonstrated mean SUVs of 5 &#x000b1; 3.2 and 3.7 &#x000b1; 0.9 in menstruating and ovulating patients, respectively, and 2.6 &#x000b1; 1.1 and 2.5 &#x000b1; 1.1 in patients in the proliferative and secretory phases, respectively<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>. Pre-menopausal patients using oral contraceptives have endometrial uptake values similar to the non-ovulating, non-menstruating phases of the cycle, likely due to the suppressive effects of contraceptives on the endometrium<sup>[<xref ref-type="bibr" rid="B45">45,</xref><xref ref-type="bibr" rid="B50">50</xref>]</sup>. To avoid a false positive interpretation of endometrial malignancy, the menstrual history should be correlated in pre-menopausal patients<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>. If there is a question of physiologic activity, repeat PET imaging may be performed in the early follicular phase of the menstrual cycle<sup>[<xref ref-type="bibr" rid="B40">40,</xref><xref ref-type="bibr" rid="B45">45</xref>]</sup>.</p><p>Cyclic abnormalities also affect endometrial activity on FDG PET. Oligomenorrhea in pre-menopausal patients has been associated with increased uptake with a mean SUV of 3.4 &#x000b1; 1.4<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>. In patients with amenorrhea, endometrial uptake resembles the values in post-menopausal patients<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>. Post-menopausal patients not receiving hormonal therapy have been shown to have a mean endometrial SUV of 1.7 &#x000b1; 0.5<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>. Hormonal therapy in post-menopausal patients has not been shown to significantly affect endometrial uptake, but has not been conclusively studied<sup>[<xref ref-type="bibr" rid="B45">45</xref>]</sup>.</p><p>Early data suggest that combined PET/CT may be useful in the management of endometrial cancer, particularly in the pre-operative detection of pelvic and para-aortic metastatic lymphadenopathy<sup>[<xref ref-type="bibr" rid="B40">40,</xref><xref ref-type="bibr" rid="B47">47,</xref><xref ref-type="bibr" rid="B51">51</xref>]</sup>. FDG PET has been used for detecting and evaluating recurrent endometrial cancer, with the advantage of imaging the entire body in a single study<sup>[<xref ref-type="bibr" rid="B51">51,</xref><xref ref-type="bibr" rid="B52">52</xref>]</sup>. Initial investigations have suggested that whole-body FDG PET in conjunction with CT and MRI may facilitate optimal management of endometrial cancer in well-selected cases<sup>[<xref ref-type="bibr" rid="B40">40</xref>]</sup>. The routine use of PET/CT for endometrial cancer staging is unwarranted. The clinical applications of PET/CT in patients with endometrial carcinoma are emerging and further studies will be required to delineate its effect on outcome<sup>[<xref ref-type="bibr" rid="B45">45,</xref><xref ref-type="bibr" rid="B46">46</xref>]</sup>. In the routine interpretation of PET/CT studies, knowledge of physiologic endometrial activity and correlation with the patient's menstrual phase are useful to avoid false positive interpretation of endometrial malignancy.</p></sec></sec><sec><title>Conclusion</title><p>Cross sectional imaging can be an important adjunct to clinical evaluation of patients with cervical, ovarian and endometrial cancer in the appropriate setting. FDG PET/CT imaging further allows functional information to be correlated with anatomic abnormalities. This information has been used to assist in staging and surveillance of disease. FDG PET/CT has also been used to predict survival of patients particularly with regard to nodal and distant spread of disease in patients with cervical cancer. The pitfalls and limitations of FDG PET/CT imaging should always be considered when evaluating patients with gynecologic malignancies. With the development of additional radiotracers, molecular imaging techniques may provide even greater sensitivity and specificity for imaging the female genital tract in the future.</p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name></person-group><article-title>Cancer statistics 2007</article-title><source>CA Cancer J Clin</source><year>2007</year><volume>57</volume><fpage>43</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">17237035</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hricak</surname><given-names>H</given-names></name><name><surname>Lacey</surname><given-names>CG</given-names></name><name><surname>Sandles</surname><given-names>LG</given-names></name><etal/></person-group><article-title>Invasive cervical carcinoma: comparison of MR imaging and surgical findings</article-title><source>Radiology</source><year>1988</year><volume>166</volume><fpage>623</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">3340756</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subak</surname><given-names>LL</given-names></name><name><surname>Hricak</surname><given-names>H</given-names></name><name><surname>Powell</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Cervical carcinoma: computed tomography and magnetic resonance imaging for preoperative staging</article-title><source>Obstet Gynecol</source><year>1995</year><volume>86</volume><fpage>46</fpage><lpage>50</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsukuma</surname><given-names>K</given-names></name><name><surname>Tsukamoto</surname><given-names>N</given-names></name><name><surname>Matsuyama</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name></person-group><article-title>Nakano H. Pre-operative CT study of lymph nodes in cervical cancer: its correlation with histological findings</article-title><source>Gyncecol Oncol</source><year>1989</year><volume>33</volume><fpage>168</fpage><lpage>71</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Choi</surname><given-names>BI</given-names></name><name><surname>Han</surname><given-names>MC</given-names></name></person-group><article-title>Uterine cervical carcinoma: evaluation of pelvic lymph node metastatis with MR imaging</article-title><source>Radiology</source><year>1994</year><volume>190</volume><fpage>807</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8115631</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WT</given-names></name><name><surname>Lam</surname><given-names>WM</given-names></name><name><surname>Yu</surname><given-names>MY</given-names></name><name><surname>Cheung</surname><given-names>TH</given-names></name><name><surname>Metreweli</surname><given-names>C</given-names></name></person-group><article-title>Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma</article-title><source>AJR Am J Roentgenol</source><year>2000</year><volume>175</volume><fpage>759</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">10954463</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheidler</surname><given-names>J</given-names></name><name><surname>Hricak</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>KK</given-names></name><name><surname>Subak</surname><given-names>L</given-names></name><name><surname>Segal</surname><given-names>MR</given-names></name></person-group><article-title>Radiological evaluation of lymph node metastases in patients with cervical cancer: a meta-analysis</article-title><source>JAMA</source><year>1997</year><volume>278</volume><fpage>1096</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">9315770</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugawara</surname><given-names>Y</given-names></name><name><surname>Eisbruch</surname><given-names>A</given-names></name><name><surname>Kosuda</surname><given-names>S</given-names></name><name><surname>Recker</surname><given-names>BE</given-names></name><name><surname>Kison</surname><given-names>PV</given-names></name><name><surname>Wahl</surname><given-names>RL</given-names></name></person-group><article-title>Evaluation of FDG PET in patients with cervical cancer</article-title><source>J Nucl Med</source><year>1999</year><volume>40</volume><fpage>1125</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10405131</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grigsby</surname><given-names>PW</given-names></name><name><surname>Siegel</surname><given-names>BA</given-names></name><name><surname>Dehdashti</surname><given-names>F</given-names></name></person-group><article-title>Lymph node staging by positron emission tomography in patients with carcinoma of the cervix</article-title><source>J Clin Oncol</source><year>2001</year><volume>19</volume><fpage>3745</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11533097</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sironi</surname><given-names>S</given-names></name><name><surname>Buda</surname><given-names>A</given-names></name><name><surname>Picchio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated PET/CT</article-title><source>Radiology</source><year>2006</year><volume>238</volume><fpage>272</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16304090</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Grigsby</surname><given-names>PW</given-names></name><name><surname>Dehdashti</surname><given-names>F</given-names></name><name><surname>Herzog</surname><given-names>TJ</given-names></name><name><surname>Siegel</surname><given-names>BA</given-names></name></person-group><article-title>FDG PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2003</year><volume>56</volume><fpage>489</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">12738325</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>C</given-names></name><name><surname>Cutin</surname><given-names>C</given-names></name><name><surname>Paul</surname><given-names>M</given-names></name></person-group><source>Synopsis of gynecologic oncology</source><year>1998</year><publisher-loc>New York</publisher-loc><publisher-name>Churchill Livingston</publisher-name></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koonings</surname><given-names>PP</given-names></name><name><surname>Campbell</surname><given-names>K</given-names></name><name><surname>Mishell</surname><given-names>DR</given-names><suffix>Jr</suffix></name><name><surname>Grimes</surname><given-names>DA</given-names></name></person-group><article-title>Relative frequency of primary ovarian neoplasms: a 10 year review</article-title><source>Obstet Gynecol</source><year>1989</year><volume>74</volume><fpage>921</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2685680</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>YY</given-names></name><name><surname>Outwater</surname><given-names>EK</given-names></name><name><surname>Kang</surname><given-names>HK</given-names></name></person-group><article-title>Imaging evaluation of ovarian masses</article-title><source>Radiographics</source><year>2000</year><volume>20</volume><fpage>1445</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10992033</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sassone</surname><given-names>AM</given-names></name><name><surname>Timor-Tritsch</surname><given-names>IE</given-names></name><name><surname>Artner</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict malignancy</article-title><source>Obstet Gynecol</source><year>1991</year><volume>78</volume><fpage>70</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2047071</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerner</surname><given-names>JP</given-names></name><name><surname>Timor-Tritsch</surname><given-names>IE</given-names></name><name><surname>Federman</surname><given-names>A</given-names></name><name><surname>Abramovich</surname><given-names>G</given-names></name></person-group><article-title>Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>170</volume><fpage>81</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">8296849</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reles</surname><given-names>A</given-names></name><name><surname>Wein</surname><given-names>U</given-names></name><name><surname>Lichtenegger</surname><given-names>W</given-names></name></person-group><article-title>Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses</article-title><source>J Clin Ultrasound</source><year>1997</year><volume>25</volume><fpage>217</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">9314102</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrazzi</surname><given-names>E</given-names></name><name><surname>Zanetta</surname><given-names>G</given-names></name><name><surname>Dordoni</surname><given-names>D</given-names></name><etal/></person-group><article-title>Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study</article-title><source>Ultrasound Obstet Gynecol</source><year>1997</year><volume>10</volume><fpage>192</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9339526</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamper</surname><given-names>UM</given-names></name><name><surname>Sheth</surname><given-names>S</given-names></name><name><surname>Abbas</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions</article-title><source>AJR Am J Roentgenol</source><year>1993</year><volume>160</volume><fpage>1225</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">8498222</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>SM</given-names></name><name><surname>Laifer-Narin</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography</article-title><source>AJR Am J Roentgenol</source><year>1995</year><volume>164</volume><fpage>381</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7839975</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>DL</given-names></name><name><surname>Frates</surname><given-names>MC</given-names></name><name><surname>Laing</surname><given-names>FC</given-names></name><etal/></person-group><article-title>Ovarian masses: can benign and malignant lesions be differentiated with color and pulsed Doppler US?</article-title><source>Radiology</source><year>1994</year><volume>190</volume><fpage>333</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">8284377</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>J</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Hartenbach</surname><given-names>E</given-names></name><etal/></person-group><article-title>Flow characteristics in benign and malignant gynecologic tumors using transvaginal color flow Doppler</article-title><source>Obstet Gynecol</source><year>1994</year><volume>83</volume><fpage>125</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">8272293</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>KA</given-names></name></person-group><article-title>Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings</article-title><source>Radiology</source><year>1994</year><volume>191</volume><fpage>63</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8134599</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz</surname><given-names>AB</given-names></name><name><surname>Tsimikas</surname><given-names>JV</given-names></name><name><surname>Tempany</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis &#x02013; report of the Radiology Diagnostic Oncology Group</article-title><source>Radiology</source><year>1999</year><volume>212</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">10405715</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegelman</surname><given-names>ES</given-names></name><name><surname>Outwater</surname><given-names>EK</given-names></name></person-group><article-title>Tissue characterization in the female pelvis</article-title><source>Radiology</source><year>1999</year><volume>212</volume><fpage>5</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">10405714</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubner</surname><given-names>KF</given-names></name><name><surname>McDonald</surname><given-names>TW</given-names></name><name><surname>Niethammer</surname><given-names>JG</given-names></name><name><surname>Smith</surname><given-names>GT</given-names></name><name><surname>Gould</surname><given-names>HR</given-names></name><name><surname>Buonocore</surname><given-names>E</given-names></name></person-group><article-title>Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[<sup>18</sup>F] deoxyglucose (2-[<sup>18</sup>F] FDG)</article-title><source>Gynecol Oncol</source><year>1993</year><volume>51</volume><fpage>197</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">8276294</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Alavi</surname><given-names>A</given-names></name></person-group><article-title>PET imaging in gynecologic malignancies</article-title><source>Radiol Clin North Am</source><year>2004</year><volume>42</volume><fpage>1155</fpage><lpage>67 (</lpage><comment>ix; review)</comment><pub-id pub-id-type="pmid">15488564</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawahara</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Kurokawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography</article-title><source>J Comput Assist Tomogr</source><year>2004</year><volume>28</volume><fpage>505</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15232382</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grab</surname><given-names>D</given-names></name><name><surname>Flock</surname><given-names>F</given-names></name><name><surname>Stohr</surname><given-names>I</given-names></name><etal/></person-group><article-title>Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography</article-title><source>Gynecol Oncol</source><year>2000</year><volume>77</volume><fpage>454</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10831359</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenchel</surname><given-names>S</given-names></name><name><surname>Grab</surname><given-names>D</given-names></name><name><surname>Nuessle</surname><given-names>K</given-names></name><etal/></person-group><article-title>Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings</article-title><source>Radiology</source><year>2002</year><volume>223</volume><fpage>780</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12034950</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Kang</surname><given-names>KW</given-names></name><name><surname>Roh</surname><given-names>JW</given-names></name><name><surname>Sim</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>ES</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name></person-group><article-title>Incidental ovarian <sup>18</sup>F-FDG accumulation on PET: correlation with the menstrual cycle</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2005</year><volume>32</volume><fpage>757</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15772859</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>RE</given-names></name><name><surname>Duska</surname><given-names>LR</given-names></name><name><surname>Lambrou</surname><given-names>NC</given-names></name><etal/></person-group><article-title>A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography</article-title><source>Cancer</source><year>2000</year><volume>89</volume><fpage>1532</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11013368</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>Y</given-names></name><name><surname>Kurokawa</surname><given-names>T</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer</article-title><source>AJR Am J Roentgenol</source><year>2004</year><volume>182</volume><fpage>227</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">14684544</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>CC</given-names></name><name><surname>Liu</surname><given-names>RS</given-names></name><name><surname>Wang</surname><given-names>PH</given-names></name><name><surname>Ng</surname><given-names>HT</given-names></name><name><surname>Yeh</surname><given-names>SH</given-names></name></person-group><article-title>Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report</article-title><source>J Reprod Med</source><year>1999</year><volume>44</volume><fpage>775</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10509300</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannu</surname><given-names>HK</given-names></name><name><surname>Bristow</surname><given-names>RE</given-names></name><name><surname>Montz</surname><given-names>FJ</given-names></name><name><surname>Fishman</surname><given-names>EK</given-names></name></person-group><article-title>Multidetector CT of peritoneal carcinomatosis from ovarian cancer</article-title><source>Radiographics</source><year>2003</year><volume>23</volume><fpage>687</fpage><lpage>701 (review)</lpage><pub-id pub-id-type="pmid">12740470</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakomoto</surname><given-names>Y</given-names></name><name><surname>Saga</surname><given-names>T</given-names></name><name><surname>Ishimori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical value of positron emission tomography with FDG for recurrent ovarian cancer</article-title><source>AJR Am J Roentgenol</source><year>2001</year><volume>176</volume><fpage>1449</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">11373212</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picchio</surname><given-names>M</given-names></name><name><surname>Sironi</surname><given-names>S</given-names></name><name><surname>Messa</surname><given-names>C</given-names></name><etal/></person-group><article-title>Advanced ovarian carcinoma: usefulness of [(18)F] FDG PET in combination with CT for lesion detection after primary treatment</article-title><source>Q J Nucl Med</source><year>2003</year><volume>47</volume><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">12865867</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bristow</surname><given-names>RE</given-names></name><name><surname>del Carmen</surname><given-names>MG</given-names></name><name><surname>Pannu</surname><given-names>HK</given-names></name><etal/></person-group><article-title>Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT</article-title><source>Gynecol Oncol</source><year>2003</year><volume>90</volume><fpage>519</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">13678719</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amant</surname><given-names>F</given-names></name><name><surname>Moerman</surname><given-names>P</given-names></name><name><surname>Neven</surname><given-names>P</given-names></name><name><surname>Timmerman</surname><given-names>D</given-names></name><name><surname>Van Limbergen</surname><given-names>E</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name></person-group><article-title>Endometrial cancer</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>491</fpage><lpage>505</lpage><pub-id pub-id-type="pmid">16084259</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>TC</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name></person-group><article-title>Positron emission tomography in gynecologic cancer</article-title><source>Semin Nucl Med</source><year>2006</year><volume>36</volume><fpage>93</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">16356798</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jobo</surname><given-names>T</given-names></name><name><surname>Sato</surname><given-names>R</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>J</given-names></name><name><surname>Kuramoto</surname><given-names>H</given-names></name></person-group><article-title>Lymph node pathway in the spread of endometrial carcinoma</article-title><source>Eur J Gynaecol Oncol</source><year>2005</year><volume>26</volume><fpage>167</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15857023</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinkel</surname><given-names>K</given-names></name><name><surname>Kaji</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>KK</given-names></name><etal/></person-group><article-title>Radiologic staging in patients with endometrial cancer: a meta-analysis</article-title><source>Radiology</source><year>1999</year><volume>212</volume><fpage>711</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10478237</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frei</surname><given-names>KA</given-names></name><name><surname>Kinkel</surname><given-names>K</given-names></name></person-group><article-title>Staging endometrial cancer: role of magnetic resonance imaging</article-title><source>J Magn Reson Imaging</source><year>2001</year><volume>13</volume><fpage>850</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">11382943</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frei</surname><given-names>KA</given-names></name><name><surname>Kinkel</surname><given-names>K</given-names></name><name><surname>Bonel</surname><given-names>HM</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Zaloudek</surname><given-names>C</given-names></name><name><surname>Hricak</surname><given-names>H</given-names></name></person-group><article-title>Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging-a meta-analysis and Bayesian analysis</article-title><source>Radiology</source><year>2000</year><volume>216</volume><fpage>444</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10924568</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lerman</surname><given-names>H</given-names></name><name><surname>Metser</surname><given-names>U</given-names></name><name><surname>Grisaru</surname><given-names>D</given-names></name><name><surname>Fishman</surname><given-names>A</given-names></name><name><surname>Lievshitz</surname><given-names>G</given-names></name><name><surname>Even-Sapir</surname><given-names>E</given-names></name></person-group><article-title>Normal and abnormal <sup>18</sup>F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT</article-title><source>J Nucl Med</source><year>2004</year><volume>45</volume><fpage>266</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">14960646</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grisaru</surname><given-names>D</given-names></name><name><surname>Almog</surname><given-names>B</given-names></name><name><surname>Levine</surname><given-names>C</given-names></name><etal/></person-group><article-title>The diagnostic accuracy of <sup>18</sup>F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies</article-title><source>Gynecol Oncol</source><year>2004</year><volume>94</volume><fpage>680</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15350358</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horowitz</surname><given-names>NS</given-names></name><name><surname>Dehdashti</surname><given-names>F</given-names></name><name><surname>Herzog</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Prospective evaluation of FDG PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer</article-title><source>Gynecol Oncol</source><year>2004</year><volume>95</volume><fpage>546</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15581961</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakahara</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>H</given-names></name><name><surname>Ide</surname><given-names>M</given-names></name><etal/></person-group><article-title>F-18 FDG uptake in endometrial cancer</article-title><source>Clin Nucl Med</source><year>2001</year><volume>26</volume><fpage>82</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11139071</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentz</surname><given-names>SS</given-names></name></person-group><article-title>Endometrial carcinoma diagnosed by positron emission tomography: a case report</article-title><source>Gynecol Oncol</source><year>2002</year><volume>86</volume><fpage>223</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">12144832</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobo</surname><given-names>RA</given-names></name><name><surname>Stanczyk</surname><given-names>FZ</given-names></name></person-group><article-title>New knowledge in the physiology of hormonal contraceptives</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>170</volume><issue>5 Pt 2</issue><fpage>1499</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">8178898</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saga</surname><given-names>T</given-names></name><name><surname>Higashi</surname><given-names>T</given-names></name><name><surname>Ishimori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Clinical value of FDG PET in the follow up of post-operative patients with endometrial cancer</article-title><source>Ann Nucl Med</source><year>2003</year><volume>17</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">12846541</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belhocine</surname><given-names>T</given-names></name><name><surname>De Barsy</surname><given-names>C</given-names></name><name><surname>Hustinx</surname><given-names>R</given-names></name><name><surname>Willems-Foidart</surname><given-names>J</given-names></name><etal/></person-group><article-title>Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2002</year><volume>29</volume><fpage>1132</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12192557</pub-id></element-citation></ref></ref-list></back></article>